|
UBE2Q2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.57105448042694E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.40899555648389E-11 |
| Normal-vs-Stage2 |
2.02270000004834E-06 |
| Normal-vs-Stage3 |
1.70820024791851E-10 |
| Normal-vs-Stage4 |
2.09487982516521E-12 |
| Stage1-vs-Stage2 |
9.851200E-01 |
| Stage1-vs-Stage3 |
5.032200E-01 |
| Stage1-vs-Stage4 |
3.544600E-03 |
| Stage2-vs-Stage3 |
6.757200E-01 |
| Stage2-vs-Stage4 |
5.634000E-02 |
| Stage3-vs-Stage4 |
4.973600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.55686574743186E-12 |
| Normal-vs-AfricanAmerican |
2.013900E-04 |
| Normal-vs-Asian |
1.52419998844522E-09 |
| Caucasian-vs-AfricanAmerican |
6.018600E-01 |
| Caucasian-vs-Asian |
6.074600E-01 |
| AfricanAmerican-vs-Asian |
4.908000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.62490004679472E-09 |
| Normal-vs-Female |
2.25131024933489E-12 |
| Male-vs-Female |
9.089600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.66419997174694E-09 |
| Normal-vs-Age(41-60Yrs) |
8.19988521527648E-12 |
| Normal-vs-Age(61-80Yrs) |
4.19380086214005E-11 |
| Normal-vs-Age(81-100Yrs) |
1.570060E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.600000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.573850E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.799600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.857000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.558600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.149400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.838000E-01 |
| Classical-VS-Follicular |
6.747400E-01 |
| Classical-VS-Other |
6.415600E-01 |
| Classical-VS-Normal |
7.26407822781994E-12 |
| Tall-VS-Follicular |
9.686600E-01 |
| Tall-VS-Other |
7.722000E-01 |
| Tall-VS-Normal |
1.92519999997476E-06 |
| Follicular-VS-Other |
8.168600E-01 |
| Follicular-VS-Normal |
1.10849999956919E-07 |
| Other-VS-Normal |
3.601300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.41480169194119E-11 |
| Normal-vs-N1 |
3.50539597349098E-11 |
| N0-vs-N1 |
1.206200E-01 |
|
|
